Updating on primary fallopian tube carcinoma

Acta Obstetricia et Gynecologica Scandinavica

Volumn 86, Issue 12, 2007, Pages 1419-1426

  Riska, Annika ^a   Leminen, Arto ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Incidence; Parity; Primary fallopian tube carcinoma; Protective factors; Risk factors

Indexed keywords

ANTIINFECTIVE AGENT; CARBOPLATIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE;

BLADDER CANCER; BREAST CANCER; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; ECHOGRAPHY; FEMALE; HUMAN; INCIDENCE; LEUKEMIA; LUNG CANCER; OVARY CANCER; PARITY; PATHOGENESIS; PRIMARY FALLOPIAN TUBE CARCINOMA; PRIORITY JOURNAL; REVIEW; UTERINE TUBE CARCINOMA;

AGED; CA-125 ANTIGEN; CHORIONIC GONADOTROPIN; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; TRYPSIN INHIBITOR, KAZAL PANCREATIC;

EID: 36248931671     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340701771034     Document Type: Review

References (59)

1. Baekelandt M, Jorunn Nesbakken A, Kristensen GB, Trope CG, Abeler VM. Carcinoma of the fallopian tube. Cancer. 2000;89:2076-84.
2. Schink J, Lurain J. Rare gynecological malignancies. Curr Opin Obstet Gynecol. 1991;3:78-90.
3. Pettersson F. Staging rules for gestational trophoblastic tumors and fallopian tube cancer. Acta Obstet Gynecol Scand. 1992;71:224-5.
4. Alvarado-Cabrero I, Young RH, Vamvakas EC, Scully RE. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol. 1999;72:367-79.
5. Riska A, Alfthan H, Finne P, Jalkanen J, Sorvari T, Stenman UH, et al. Preoperative serum hCGbeta as a prognostic marker in primary fallopian tube carcinoma. Tumor Biol. 2006;27:43-9.
6. Rosenblatt KA, Weiss NS, Schwartz SM. Incidence of malignant fallopian tube tumors. Gynecol Oncol. 1989;35:236-9.
7. National Cancer Institute. SEER program. 12 geographic areas for 1995-1999. Bethesda, MD: National Cancer Institute, Cancer Statistic Branch; 2001.
8. Clayton NL, Jaaback KS, Hirschowitz L. Primary fallopian tube carcinoma - the experience of a UK cancer centre and a review of the literature. J Obstet Gynaecol. 2005;25:694-702.
9. Pfeiffer P, Mogensen H, Amtrup F, Honore E. Primary carcinoma of the fallopian tube. A retrospective study of patients reported to the Danish cancer registry in a five-year period. Acta Oncol. 1989;28:7-11.
10. Hellström AC, Silfverswärd C, Nilsson B, Pettersson F. Carcinoma of the fallopian tube. A clinical and histopathologic review. The Radiumhemmet series. Int J Gynecol Cancer. 1994;4:395-400.
11. Riska A, Leminen A, Pukkala E. Sociodemographic determinants of incidence of primary fallopian tube carcinoma, Finland 1953-97. Int J Cancer. 2003;104:643-5.
12. Vasama-Neuvonen K, Pukkala E, Paakkulainen H, Mutanen P, Weiderpass E, Boffetta P, et al. Ovarian cancer and occupational exposures in Finland. Am J Ind Med. 1999;36:83-9.
13. Demopoulos RI, Aronov R, Mesia A. Clues to the pathogenesis of fallopian tube carcinoma: a morphological and immunohistochemical case control study. Int J Gynecol Pathol. 2001;20:128-32.
14. Gungor T, Keskin HL, Zergeroglu S, Keskin EA, Yalcin H, Aydogdu T, et al. Tuberculous salpingitis in two of five primary fallopian tube carcinomas. J Obstet Gynaecol. 2003;23:193-5.
15. Riska A, Finne P, Alfthan H, Anttila T, Jalkanen J, Sorvari T, et al. Past chlamydial infection is not associated with primary fallopian tube carcinoma. Eur J Cancer. 2006;42:1835-8.
16. Riska A, Finne P, Koskela P, Alfthan H, Jalkanen J, Lehtinen M, et al. Human papillomavirus infection and primary fallopian tube carcinoma: a seroepidemiological study. BJOG. 2007;114:425-9.
17. Heselmeyer K, Hellström AC, Blegen H, Schrock E, Silfverward C, Shah K, et al. Primary carcinoma of fallopian tube: comparative genomic hybridization reveals high genetic instability and a specific, recurring pattern of chromosomal aberrations. Int J Gynecol Pathol. 1998;17:245-54.
18. Riska A, Sund R, Pukkala E, Gissler M, Leminen A. Parity, tubal sterilization, hysterectomy and risk of primary fallopian tube carcinoma in Finland, 1975-2004. Int J Cancer. 2007;120:1351-4.
19. Hinkula M, Pukkala E, Kyyronen P, Kauppila A. Incidence of ovarian cancer of grand multigparous women - a population-based study in Finland. Gynecol Oncol. 2006;1:207-11.
20. Hinkula M, Pukkala E, Kyyronen P, Kauppila A. Grand multiparity and incidence of endometrial cancer: a population-based study in Finland. Int J Cancer. 2002;6:912-5.
21. Hinkula M, Pukkala E, Kyyronen P, Kauppila A. Grand multiparity and the risk of breast cancer: population-based study in Finland. Cancer Causes Control. 2001;12:491-500.
22. Lambe M, Wuu J, Weiderpass E, Hsieh CC. Childbearing at older age and endometrial cancer risk (Sweden). Cancer Causes Control. 1999;10:43-9.
23. Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol. 2001;80:341-5.
24. Carcangiu ML, Radice P, Manoukian S, Spatti G, Gobbo M, Pensotti V, et al. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol. 2004;23:35-40.
25. Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol. 2005;106:1327-34.
26. Rosen AC, Ausch C, Klein M, Graf AH, Metzenbauer M, Philipp K, et al. p53 expression in fallopian tube carcinomas. Cancer Lett. 2000;156:1-7.
27. Vousden KH, Lane DP. P53 in health and disease. Nat Rev Mol Cell Biol. 2007;8:275-83.
28. Zheng W, Sung CJ, Cao P, Zhang ZF, Cai R, Godwin TA, et al. Early occurrence and prognostic significance of p53 alteration in primary carcinoma of the fallopian tube. Gynecol Oncol. 1997;64:38-48.
29. Chung TK, Cheung TH, To KF, Wong YF. Overexpression of p53 and HER-2/neu and c-myc in primary fallopian tube carcinoma. Gynecol Obstet Invest. 2000;49:47-51.
30. Ajithkumar TV, Minimole AL, John MM, Ashokkumar OS. Primary fallopian tube carcinoma. Obstet Gynecol Surv. 2005;60:247-52.
31. Tavassoli FA, Devilee P, editors. World Health Organization Classification of Tumors. Pathology and genetics of tumors of the breast and female genital organs. IARC Press: Lyon; 2003.
32. Kol S, Gal D, Friedman M, Paldi E. Preoperative diagnosis of fallopian tube carcinoma by transvaginal sonography and CA-125. Gynecol Oncol. 1990;37:129-31.
33. Hosokawa C, Tsubakimoto M, Inoue Y, Nakamura T. Bilateral primary fallopian tube carcinoma: findings on sequential MRI. AJR Am J Roentgenol. 2006;186:1046-50.
34. Niloff JM, Klug TL, Schaetzl E, Zurawski VR Jr, Knapp RC, Bast RC Jr. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol. 1984;148:1057-8.
35. Lootsma-Miklosova E, Aalders JG, Willemse PH, de Bruijn HW. Levels of CA 125 in patients with recurrent carcinoma of the fallopian tube: two case histories. Eur J Obstet Gynecol Reprod Biol. 1987;24:231-5.
36. Rosen AC, Klein M, Rosen HR, Graf AH, Lahousen M, Reiner A, et al. Preoperative and postoperative CA-125 serum levels in primary fallopian tube carcinoma. Arch Gynecol Obstet. 1994;255:65-8.
37. Hefler LA, Rosen AC, Graf AH, Lahousen M, Klein M, Leodolter S, et al. The clinical value of serum concentrations of cancer antigen 125 in patients with primary fallopian tube carcinoma: a multicenter study. Cancer. 2000;89:1555-60.
38. Braunstein GD, Vaitukaitis JL, Ross GT. The in vivo behavior of human chorionic gonadotropin after dissociation into subunits. Endocrinology. 1972;91:1030-6.
39. Vartiainen J, Lehtovirta P, Finne P, Stenman UH, Alfthan H. Preoperative serum concentration of hCGbeta as a prognostic factor in ovarian cancer. Int J Cancer. 2001;95:313-6.
40. Baekelandt M, Kockx M, Wesling F, Gerris J. Primary adenocarcinomas of fallopian tube. Review of the literature. Int J Gynecol Cancer. 1993;3:65-71.
41. Nordin AJ. Primary carcinoma of the fallopian tube: a 20-year literature review. Obstet Gynecol Surv. 1994;49:349-61.
42. Obermair A, Taylor KH, Janda M, Nicklin JL, Crandon AJ, Perrin L. Primary fallopian tube carcinoma: the Queensland experience. Int J Gynecol Cancer. 2001;11:69-72.
43. Benoit MF, Hannigan EV. A 10-year review of primary fallopian tube cancer at a community hospital: a high association of synchronous and metachronous cancers. Int J Gynecol Cancer. 2006;6:29-35.
44. Pectasides D, Pectasides E, Economopoulos T. Fallopian tube carcinoma: a review. Oncologist. 2006;11:902-12.
45. Plentl A, Friedman E. Lymphatics of the fallopian tube. In: Plentl A, Friedman E, editors. Lymphatic system of the female genitalia. Philadelphia, PA: WB Saunders; 1971. p. 153-67.
46. Tamimi H, Figge D. Adenocarcinoma of the uterine tube:-potential for lymph node metastases. Am J Obstet Gynecol. 1981;141:132-7.
47. di Re E, Grosso G, Raspagliesi F, Baiocchi G. Fallopian tube cancer: incidence and role of lymphatic spread. Gynecol Oncol. 1996;62:199-202.
48. Sedlis A. Carcinoma of the fallopian tube. Surg Clin North Am. 1978;58:121-9.
49. Gadducci A. Current management of fallopian tube carcinoma. Curr Opin Obstet Gynecol. 2002;14:27-32.
50. Tresukosol D, Kudelka AP, Edwards CL, Fromm GL, Mante R, Kavanagh JJ. Primary fallopian tube adenocarcinoma: clinical complete response after salvage treatment with high-dose paclitaxel. Gynecol Oncol. 1995;58:258-61.
51. Gemignani ML, Hensley ML, Cohen R, Venkatraman E, in carcinoma of the fallopian tube. Gynecol Oncol. 2001;80:16-20.
52. Kosary C, Trimble EL. Treatment and survival for women with fallopian tube carcinoma: a population-based study. Gynecol Oncol. 2002;86:190-1.
53. Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes E, Steger M, Nelson-Taylor T, et al. Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. J Clin Oncol. 2000;18:2733-9.
54. Riska A, Pukkala E, Scelo G, Mellemkjaer L, Hemminki K, Weiderpass Vainio E, et al. Second primary malignancies in females with primary fallopian tube carcinoma. Int J Cancer. 2007;120:2047-61.
55. Iles RK, Persad R, Trivedi M, Sharma KB, Dickinson A, Smith P, et al. Urinary concentration of human chorionic gonadotrophin and its fragments as a prognostic marker in bladder cancer. Br J Urol. 1996;77:61-9.
56. Pierce JG, Parsons TF. Glycoprotein hormones: structure and function. Annu Rev Biochem. 1981;50:465-95.
57. Butler SA, Ikram MS, Mathieu S, Iles RK. The increase in bladder carcinoma cell population induced by the free beta subunit of human chorionic gonadotrophin is a result of an anti-apoptosis effect and not cell proliferation. Br J Cancer. 2000;82:1553-6.
58. Iles RK. Ectopic hCGbeta expression by epithelial cancer: malignant behaviour, metastasis and inhibition of tumor cell apoptosis. Mol Cell Endocrinol. 2007;260-72:264-70.
59. Delves PJ, Iles RK, Roitt IM, Lund T. Designing a new generation of anti-hCG vaccines for cancer therapy. Mol Cell Endocrinol. 2006;260-2:276-84.